1 – 10 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia : A population-based study in Sweden
(
- Contribution to journal › Letter
-
Mark
Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden
(
- Contribution to journal › Letter
-
Mark
Early death rates remain high in high-risk APL : Update from the Swedish Acute Leukemia Registry 1997-2013
(
- Contribution to journal › Letter
-
Mark
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
(
- Contribution to journal › Article
- 2016
-
Mark
Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
(
- Contribution to journal › Article
- 2014
-
Mark
Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience.
(
- Contribution to journal › Article
- 2011
-
Mark
Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry
(
- Contribution to journal › Article
- 2010
-
Mark
Superior long-term survival with a high rate of allogeneic stem cell transplantation in AML (non-APL) patients below 60 years of age
2010) 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting In Bone Marrow Transplantation 45. p.9-10(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
(
- Contribution to journal › Article